MicroRNA-126 selected with broad-spectrum analysis of microRNAs – a new predictive factor for the effectiveness of immunotherapy or chemoimmunotherapy in advanced NSCLC patients?
IntroductionExpression of PD-L1 on cancer cells is the only validated predictive factor for immunotherapy in NSCLC (Non-Small Cell Lung Cancer) patients. However, on this basis, it is difficult to predict the occurrence of resistance to immune checkpoint inhibitors (ICIs). MicroRNAs are widely studi...
| Main Authors: | , , , , , , , , , |
|---|---|
| פורמט: | Article |
| שפה: | English |
| יצא לאור: |
Frontiers Media S.A.
2024-02-01
|
| סדרה: | Frontiers in Immunology |
| נושאים: | |
| גישה מקוונת: | https://www.frontiersin.org/articles/10.3389/fimmu.2024.1344858/full |